SBIR/STTR Research Award
Noninvasive Treatment of Biofilm on Metallic Implants
Award amount
$1,342,570Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Solenic Medical Inc
- Proposal award date
- 2020-09-14
- Contract end date
- 2022-08-31
- UEI
- H5F1MMEAMCM3
- Solicitation number
- PA19-272
- Topic code
- NIAID
Research abstract
Project Summary
Biofilm-related infections are a major complication for orthopedic implants used to replace or repair injured bones
and joints. Biofilms are aggregates of bacteria and extracellular substances which can form on any surface,
including the surface of implanted medical devices. Bacteria within biofilms are protected from antibiotics and
the immune system, and can cause recurrent infection even after a prolonged course of therapy. The treatment
of these infections is prolonged and costly; removal and replacement of the infected hardware, weeks of antibiotic
administration, and extended hospital stays are usually required. Approximately 70 percent of these biofilm-
infections are caused by gram-positive pathogens, such as Staphylococcus aureus, with the remaining caused
by gram-negative pathogens, such as Pseudomonas aeruginosa. Increasing rates of antibiotic resistance in
these pathogens are further complicating patient treatment. An innovative non-invasive approach for the
treatment of biofilm on metallic implants can be achieved through the use of an alternating magnetic
fields (AMF). When metal prostheses are exposed to AMF, electrical currents are induced on their surface,
resulting in rapid heating which can destroy biofilm. This method of treatment is highly effective at killing the
bacterial components of the biofilm, and can be used in concert with traditional antimicrobials to achieve
complete treatment of the infection. The research team hypothesizes that focused heating of an in vivo metallic
implant surface through the delivery of AMF will be bactericidal to pathogens embedded within an attached
biofilm, will increase their sensitivity to antimicrobial agents and will be safe in vivo. The overall goals of this
study are to evaluate biofilm eradication by AMF exposure in both small and large animal models of
implant infection, as well as design and characterize a prototype AMF device suitable for treating human
implant infections. This proposal aims to answer critical questions regarding the optimal power, temperature,
and total exposure time that will be both safe and effective. This would represent a significant advance in the
ability to treat implants in situ, avoiding millions of surgeries and the corresponding billions of dollars associated
with them.Project Narrative
Biofilm-related infections are a major complication for orthopedic implants used to replace or repair injured bones
and joints. The treatment of these infections is prolonged and costly; removal and replacement of the infected
hardware, weeks of antibiotic administration, and extended hospital stays usually are required. An innovative
non-invasive approach for the treatment of biofilm on metallic implants can be achieved through the use of
alternating magnetic fields (AMF). When metal prostheses are exposed to AMF, electrical currents are induced
on their surface, resulting in rapid heating which can destroy biofilm. The overall goals of this study are to
evaluate biofilm eradication by AMF exposure in both small and large animal models of implant infection, as well
as design and characterize a prototype AMF device suitable for treating human implant infections.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients